Novartis | NVS - Выручка от реализации

Биржевая цена
148.18
Изменение за день
-1.41 -0.94%
Ежемесячно
-11.24%
Ежегодный
31.51%
Q1 прогноз
144.45




Продажи Изменить Дата
AbbVie USD 16.62B 840M 2025-12
Amgen USD 9.9B 340M 2025-12
AstraZeneca USD 15.5B 313M 2025-12
Bausch Health Companies USD 2.8B 120M 2025-12
Biogen USD 2.28B 250M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Canopy Growth CAD 74.54M 7.86M 2025-12
Corcept Therapeutics USD 202.12M 5.48M 2025-12
Drreddys Laboratories INR 87.27B 1.82B 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Gilead Sciences USD 7.93B 130M 2025-12
GlaxoSmithKline GBP 8.62B 73M 2025-12
Glaxosmithkline GBP 11.46B 59.16M 2025-12
J&J USD 24.6B 610M 2025-12
Merck USD 16.4B 880M 2025-12
Novartis USD 13.86B 50M 2025-12
Novartis USD 13.86B 498M 2025-12
Pacira USD 196.87M 17.35M 2025-12
Perrigo USD 1.11B 70M 2025-12
Pfizer USD 17.58B 880M 2025-12
Phibro Animal Health USD 373.91M 10.02M 2025-12
Prestige Brands USD 283.44M 9.34M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sanofi EUR 11.3B 1.13B 2025-12
Sanofi EUR 12.2B 3.19B 2025-12
Supernus Pharmaceuticals USD 211.6M 19.5M 2025-12
Zoetis USD 2.4B 0 2025-12